Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 378; H. 26; S. 2486 - 2496
Hauptverfasser: Castro, Mario, Corren, Jonathan, Pavord, Ian D, Maspero, Jorge, Wenzel, Sally, Rabe, Klaus F, Busse, William W, Ford, Linda, Sher, Lawrence, FitzGerald, J. Mark, Katelaris, Constance, Tohda, Yuji, Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Khan, Asif, Chao, Jingdong, Martincova, Renata, Graham, Neil M.H, Hamilton, Jennifer D, Swanson, Brian N, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 28.06.2018
Schlagworte:
Adolescent
Adult
Age
Anti-Asthmatic Agents - adverse effects
Anti-Asthmatic Agents - pharmacology
Anti-Asthmatic Agents - therapeutic use
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Asthma
Asthma - classification
Asthma - drug therapy
Biomarkers
Blood
Bronchodilator Agents - therapeutic use
Bronchodilators
Child
Clinical medicine
Committees
Cytokines
Double-Blind Method
Drug dosages
Drug Therapy, Combination
Eosinophilia
Eosinophilia - chemically induced
Female
Forced Expiratory Volume - drug effects
Humans
Immunotherapy
Inflammation
Injections, Subcutaneous - adverse effects
Intention to Treat Analysis
Interleukin 13
Interleukin 4
Intervention
Leukocytes (eosinophilic)
Male
Medicine
Middle Aged
Monoclonal antibodies
Patient safety
Pharmaceuticals
Population
Questionnaires
Receptors, Interleukin-4 - antagonists & inhibitors
Respiratory function
Safety
Young Adult
Los Angeles California
United States > US
California
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1804092